港股午评 恒生指数早盘涨0.65% 生物医药板块反弹

Group 1 - The Hang Seng Index rose by 0.65%, gaining 165 points to close at 25,663 points, while the Hang Seng Tech Index increased by 1.14% [1] - New listings in the Hong Kong stock market included Zhihui Mining (02546), which surged over 110% on its debut, and Xidi Zhijia (03881), which fell over 8% [1] - The U.S. Senate passed a revised version of the Biosecurity Act as part of the National Defense Authorization Act for fiscal year 2026, leading to a significant rebound in pharmaceutical stocks, with WuXi Biologics (02269) rising over 6% and 3SBio (01530) increasing by 3.7% [1] Group 2 - HAP Pharmaceuticals-B (02142) saw a nearly 7% increase after signing a business development deal worth over $1 billion with Bristol-Myers Squibb [2] - China Duty Free Group (01880) rebounded nearly 7% after winning bids for two major airport duty-free projects in Shanghai, with market attention on the results of the capital airport bidding [3] - Youjia Innovation (02431) rose over 12% as the large-scale rollout of L3 technology approaches, with the company having preemptively positioned itself for L2 and L4 technologies [4] Group 3 - Nine Dragons Paper (02689) increased by over 3% as the industry leader announced a series of shutdown plans to support price and inventory levels before the Spring Festival [5] - Southern Manganese (01091) rose over 9% due to multiple factors driving the continuous increase in electrolytic manganese prices [6] - Yangtze Optical Fibre and Cable (06869) surged over 10%, with a cumulative increase of over 30% in the past three days, driven by sustained demand for optical fibres and cables from AI [7] Group 4 - Ganwan (09890) increased by over 5% after issuing zero-coupon convertible bonds at a premium, raising HKD 450 million to enhance its "AI + gaming" initiatives [8] - Liqin Resources (02245) rose over 9% as Indonesia plans to significantly reduce its nickel ore production targets by 2026 [9] - Shenzhou International (02313) fell over 3% as its major client Nike reported a 32% year-on-year decline in net profit for the second fiscal quarter [10]